Management of recurrent vulvovaginal candidiasis: unresolved issues.

Abstract

The introduction and widespread use of long-term maintenance suppressive fluconazole prophylaxis for recurrent vulvovaginal candidiasis (RVVC) has improved the quality of life for thousands of women worldwide. Moreover, the regimen is no longer expensive, and it is safe and well tolerated. However, the regimen frequently fails to cure the condition and serves only as an effective control measure in many cases. Moreover, some women are unable to tolerate the regimen, and new curative approaches are needed. This review presents the limitations of this suppressive regimen and a discussion of the possible reasons for these limitations and failure to cure. Also, the rationale for new drug development is reviewed here.

• Authors: Jack D Sobel
• Journal: Current infectious disease reports (Curr Infect Dis Rep) Vol. 8 Issue 6 Pg. 481-6 (Nov 2006) ISSN: 1523-3847 [Print] United States
• PMID: 17064642 (Publication Type: Journal Article)